Clinical Trial: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Smoldering Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: Selinexor for the Treatment of Patients With Intermediate and High-Risk Smoldering Multiple Myeloma
Brief Summary:
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma.The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes.A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering…
Read more